Table 2.
ADC, conspicuity and signal intensity values for each of the two arms included in the study at baseline and after 6 months
| Placebo | Dutasteride | |||||
|---|---|---|---|---|---|---|
| Baseline MRI | 6-month MRI | p | Baseline MR | 6-month MRI | p | |
| ADC lesion | 0.99 (±0.24) | 0.96 (±0.23) | 0.301 | 1.01 (±0.15) | 1.08 (±0.20) | 0.069 |
| Conspicuity | 1.56 (±0.31) | 1.67 (±0.34) | 0.174 | 1.54 (±0.26) | 1.38 (±0.31) | 0.025 |
| ADC TZ | 1.46 (±0.18) | 1.39 (±0.16) | 0.061 | 1.32 (±0.14) | 1.36 (±0.14) | 0.307 |
| ADC PZ | 1.50 (±0.23) | 1.55 (±0.24) | 0.446 | 1.52 (±0.17) | 1.45 (±0.21) | 0.126 |
| SI lesion | 68.05 (±15.96) | 71.80 (±13.84) | 0.168 | 56.59 (±15.15) | 48.99 (±12.37) | <0.01 |
Note - Data are means with standard deviations in parentheses. MRI: magnetic resonance imaging; ADC: apparent diffusion coefficient (x 10-3 mm2/s); TZ: transition zone; PZ: peripheral zone; SI: signal intensity. Paired t test used for comparisons